Guangzhou Baiyunshan Pharma's Profit Falls 17% in H1

MT Newswires Live

7 hours ago

Guangzhou Baiyunshan Pharmaceutical (HKG:0874, SHA:600332) posted an attributable net profit of 2.10 billion yuan for the first half of 2026, down 17% from 2.52 billion yuan a year earlier.

Earnings per share rose to at 1.289 yuan from 1.548 yuan in the year-ago period, according to a Friday Hong Kong bourse filing.

Revenue increased 0.61% year over year to 42.1 billion yuan from 41.8 billion yuan.

The company proposed a cash dividend of 0.30 yuan per share, inclusive of tax, to all shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2661244886"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2661244886\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2661244886?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-24 09:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661244886","market":"us","top_or_hot":-1,"title":"Guangzhou Baiyunshan Pharma's Profit Falls 17% in H1","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GZPHF\">Guangzhou Baiyunshan</a> Pharmaceutical (HKG:0874, SHA:600332) posted an attributable net profit of 2.10 billion yuan for the first half of 2026, down 17% from 2.52 billion yuan a year earlier.</p><p>Earnings per share rose to at 1.289 yuan from 1.548 yuan in the year-ago period, according to a Friday Hong Kong bourse filing.</p><p>Revenue increased 0.61% year over year to 42.1 billion yuan from 41.8 billion yuan.</p><p>The company proposed a cash dividend of 0.30 yuan per share, inclusive of tax, to all shareholders.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guangzhou Baiyunshan Pharma's Profit Falls 17% in H1</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuangzhou Baiyunshan Pharma's Profit Falls 17% in H1\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-24 09:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/GZPHF\">Guangzhou Baiyunshan</a> Pharmaceutical (HKG:0874, SHA:600332) posted an attributable net profit of 2.10 billion yuan for the first half of 2026, down 17% from 2.52 billion yuan a year earlier.</p><p>Earnings per share rose to at 1.289 yuan from 1.548 yuan in the year-ago period, according to a Friday Hong Kong bourse filing.</p><p>Revenue increased 0.61% year over year to 42.1 billion yuan from 41.8 billion yuan.</p><p>The company proposed a cash dividend of 0.30 yuan per share, inclusive of tax, to all shareholders.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0097","symbol_name":"医药电商","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2661244886","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2661244886","pubTimestamp":1787533464,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guangzhou Baiyunshan Pharmaceutical  posted an attributable net profit of 2.10 billion yuan for the first half of 2026, down 17% from 2.52 billion yuan a year earlier.Earnings per share rose to at 1.289 yuan from 1.548 yuan in the year-ago period, according to a Friday Hong Kong bourse filing.Revenue increased 0.61% year over year to 42.1 billion yuan from 41.8 billion yuan.The company proposed a cash dividend of 0.30 yuan per share, inclusive of tax, to all shareholders.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK0097":"医药电商","BK0239":"医药制造","BK0028":"国家队","BK1197":"保健护理产品经销商","00874":"白云山","FCA":"First Trust China AlphaDEX Fund","BK0096":"民营医院","BK0183":"MSCI概念","BK0070":"员工持股","BK0188":"融资融券","BK1521":"挪威政府全球养老基金持仓","BK1515":"抗疫概念","BK0012":"证金概念","BK1606":"中医药概念","BK1191":"制药","BK0196":"行业龙头","BK0175":"白马股"},"translate_title":"广州白云山制药上半年利润下降17%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":0.9,"FCA":0.9,"00874":0.9},"content_text":"Guangzhou Baiyunshan Pharmaceutical (HKG:0874, SHA:600332) posted an attributable net profit of 2.10 billion yuan for the first half of 2026, down 17% from 2.52 billion yuan a year earlier.Earnings per share rose to at 1.289 yuan from 1.548 yuan in the year-ago period, according to a Friday Hong Kong bourse filing.Revenue increased 0.61% year over year to 42.1 billion yuan from 41.8 billion yuan.The company proposed a cash dividend of 0.30 yuan per share, inclusive of tax, to all shareholders.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}